Sphingomyelin enhancement of tumor therapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 30, 2007
Grant Date -
Dec 11, 2003
app pub date -
Feb 14, 2003
filing date -
Mar 25, 1999
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully